Fact CheckerSign in

NCT07365501Enrolling by invitation

Acute Effect of Nurse-assessed Remote Ischemic Preconditioning on Improving Vascular Parameters in Patients With Suspected Heart Failure With Preserved Ejection Fraction

Source: ClinicalTrials.gov · Last updated 6 Mar 2026

Brief summary (registry, in English)

The PIRIC-FEp study will be a randomized clinical trial in sedentary patients with suspected heart failure with preserved ejection fraction. Objectives: 1) To evaluate the acute efficacy of remote ischemic preconditioning performed by nurses, a noninvasive cardioprotective intervention that uses cycles of ischemia and reperfusion in the extremities, in improving vascular parameters. Methodology: Patients will be recruited in Health Centers in the city. Those assigned to the intervention group will wear a self-administered blood pressure cuff, inflated to 220 mmHg for 5 minutes, followed by 5 minutes of deflation, in repeated cycles four times. The control group will receive no intervention. All participants will be examined, at baseline, 0 minutes post intervention, 30 minutes post intervention, 60 minutes post intervention and 24 hours post intervention. Different vascular parameters will be evaluated, including peripheral and central Systolic and Blood Pressure, peripheral and central Mean Arterial Pressure, peripheral and central Pulse Pressure, Heart Rate, Cardiac Output, Stroke Volume, Peripheral Vascular Resistance, aortic Pulse Wave Velocity and Augmentation Index normalized to a heart rate of 75 beats per minute. The study will be approved by an Ethics Committee, participants will be informed and will have to sign a written consent. The statistical analysis will include three phases: verification of randomization, use of covariance models for dependent variables, and sensitivity analysis with propensity score matching. All analyses will be performed on an intention-to-treat basis.

Status (registry)
Enrolling by invitation
Study type
Interventional
Enrollment
48 (estimated)
First submitted
16 Jan 2026
Start date
1 Oct 2025
Primary completion date
28 Feb 2027
Lead sponsor
University of Castilla-La Mancha
NCT number
NCT07365501

What you commit to

  • Study type: Interventional
  • Planned participants: 48
  • From 1 Oct 2025 to the primary completion date, 28 Feb 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Non-cardiac causes of Heart Failure symptoms:
    • Significant valvular or coronary artery disease
    • Uncontrolled hypertension or arrhythmias
    • Primary cardiomyopathies
  • Significant pulmonary disease (FEV1\<50% predicted, GOLD III-IV)
  • Inability to exercise or conditions that may interfere with exercise intervention.
  • Myocardial infarction within the last 3 months.
  • Patients with diabetes and/or peripheral vascular disease.

Other

  • Comorbidity that may influence prognosis at one year.
  • Participation in another clinical trial

Who the study is looking for

  • Signs and symptoms of Heart Failure (Clinical suspicion of Heart Failure)
  • Sedentary men and women (structured exercise \<2 x 30 min/week).
  • Age ≥40 years
  • Written informed consent
  • Clinically stable for 6 weeks
  • Optimal medical treatment for ≥6 weeks.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Iván
Coordinator of this site? Confirm its status
CuencaSpainUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.